Clinical Research of Cetuximab Combined with FOLFOX Chemotherapy for Treating Metastatic Colorectal Cancer

OBJECTIVE To observe the recent efficacy and toxicity of cetuximab combined FOLFOX chemotherapy for treating metastatic colorectal cancer (MCRC). METHODS Forty-eight cases of patients with MCRC were studied. Cetuximab was administered weekly, the first loading dose was 400 mg·m^-2, maintenance dose was 250 mg·m^-2. Joint programme: oxaliplatin 85 mg·m^-2+5-fluorouracil 600 mg·m^-2+leucovorin 200 mg·m^-2, 2 weeks as a cycle. After 2 cycles of chemotherapy, recent efficacy was evaluated, the TTP and toxicity were observed. RESULTS CR 0 case, PR 39 cases, SD 9 cases, PD 0 case, the total effective rate was 81.3%, the disease control rate was 100.0%, the TTP was 9 months. The toxicity was mainly Ⅰ-Ⅱ grade. CONCLUSION Cetuximab combined with FOLFOX chemotherapy for treating MCRC can get higher efficiency, longer TTP and can improve the quality of patient’s life. It is worthy of clinical application.